Trial Profile

A Randomized, Placebo-controlled, Double-Blind Phase 2 Study to Assess Efficacy and Safety of LB54640 in Patients With Hypothalamic Obesity, With an Open-Label Extension

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 10 Mar 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

26 Feb 2026 According to a Rhythm Pharmaceuticals media release, the Company announced it completed a positive end-of-Phase-2 meeting with FDA regarding bivamelagon in acquired HO.
12 Feb 2026 Status changed from active, no longer recruiting to completed.
12 Jul 2025 According to a Rhythm Pharmaceuticals media release, data from this trial was presented at the Endocrine Societys Annual Meeting (ENDO 2025) taking place July 12 to 15 in San Francisco, CA.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com